Other languages SymBio Pharmaceuticals Limited

Equities

4582

JP3383050006

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-07-02 EDT			5-day change	1st Jan Change
162 ^JPY	0.00%		-0.61%	-34.41%

05-07	Symbio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2024	CI
04-19	SymBio Pharmaceuticals Limited announced that it has received ¥196.35 million in funding from Evolution Capital Management LLC	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Symbio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2024	05-07
SymBio Pharmaceutical's FY2023 Earnings Miss Forecast Due to Higher Than Expected Operating Loss	02-12
SymBio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2024	02-08
SymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023	02-08
SymBio Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	02-08
SymBio Pharmaceuticals Adjusts Forecasts to Reflect Shrinking Market Demand	11-15
Symbio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023	11-14
SymBio Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	11-14
SSymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023	23-08-03
SymBio Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-03
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	23-04-27
SymBio Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27
SymBio Pharmaceuticals Limited Enters into A Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases	23-04-23
SymBio Pharmaceuticals Limited Enters into Collaborative Research and Development Agreement with National Institute of Neurological Disorders and Stroke	23-03-22
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	23-02-09
SymBio Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended September 30, 2022	22-11-08
Symbio Pharmaceuticals Limited Revises Earnings Forecast for the Period from January 1, 2022 to December 31, 2022	22-11-08
SymBio Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-04
Symbio Pharmaceuticals Limited Revises Earning Guidance for Fiscal Year Ending December 31, 2022	22-08-04
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year 2022	22-05-11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages SymBio Pharmaceuticals Limited

Equities

4582

JP3383050006

Other languages

Filters